BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q4 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $5,188,295 | -19.9% | 76,220 | -3.9% | 0.18% | -16.9% |
Q2 2023 | $6,477,259 | -14.0% | 79,349 | -21.8% | 0.21% | -19.0% |
Q1 2023 | $7,529,395 | +73.7% | 101,488 | +94.1% | 0.26% | +70.8% |
Q4 2022 | $4,334,375 | -13.1% | 52,297 | +197.6% | 0.15% | -17.2% |
Q3 2022 | $4,990,000 | -59.1% | 17,572 | -50.1% | 0.19% | -14.7% |
Q2 2022 | $12,208,000 | +54.8% | 35,220 | +93.4% | 0.22% | -12.4% |
Q1 2022 | $7,888,000 | -20.4% | 18,215 | -4.9% | 0.25% | -16.7% |
Q4 2021 | $9,910,000 | -1.9% | 19,156 | -8.1% | 0.30% | -9.9% |
Q3 2021 | $10,102,000 | +2.7% | 20,847 | -4.6% | 0.33% | +0.9% |
Q2 2021 | $9,838,000 | +17.9% | 21,850 | +0.0% | 0.33% | +6.8% |
Q1 2021 | $8,342,000 | +20.1% | 21,843 | -0.1% | 0.31% | +21.3% |
Q4 2020 | $6,943,000 | +27.8% | 21,866 | -0.3% | 0.25% | +8.1% |
Q3 2020 | $5,434,000 | +9.4% | 21,936 | +16.7% | 0.24% | +7.3% |
Q2 2020 | $4,965,000 | +40.1% | 18,802 | +0.6% | 0.22% | +30.4% |
Q1 2020 | $3,544,000 | +44.1% | 18,688 | +66.9% | 0.17% | +147.1% |
Q4 2019 | $2,459,000 | +8.3% | 11,200 | -3.5% | 0.07% | +13.3% |
Q3 2019 | $2,270,000 | +651.7% | 11,603 | +662.9% | 0.06% | +650.0% |
Q1 2019 | $302,000 | +32.5% | 1,521 | -3.6% | 0.01% | +33.3% |
Q4 2018 | $228,000 | -29.2% | 1,577 | 0.0% | 0.01% | -25.0% |
Q3 2018 | $322,000 | +38.2% | 1,577 | 0.0% | 0.01% | +33.3% |
Q2 2018 | $233,000 | -5.3% | 1,577 | -3.1% | 0.01% | 0.0% |
Q1 2018 | $246,000 | +18.8% | 1,628 | +2.0% | 0.01% | +20.0% |
Q4 2017 | $207,000 | – | 1,596 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |